Dirk Rainwater, MD
General Practice · Jonesboro, LANPI 1043286230
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by GSK at 32.1% of the total. Reporting peaked in 2019 at $1,395 and has fallen 81.8% since, to $254 in 2025. Among general practice clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $13.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$544
- Merck$343
- AstraZeneca$335
- Lilly USA, LLC$239
- Amgen$162
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,949100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $1,269 |
| AbbVie(2 entities) | 59 | $544 |
| Merck | 27 | $343 |
| AstraZeneca(2 entities) | 15 | $335 |
| Lilly USA, LLC | 9 | $239 |
| Amgen | 4 | $162 |
| Pfizer | 8 | $116 |
| Novo Nordisk | 7 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $78 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Abbott | 1 | $64 |
| Bayer | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $52 |
| Corcept Therapeutics | 2 | $48 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 3 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Tris Pharma Inc | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Bioventus LLC | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $11 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- TRULICITY$125
- BREZTRI$125
- Repatha$125
How this compares
$3,955 in reported general payments places this provider in the 95th percentile of 1,221 general practice providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,878 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $599 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $452 |
| Levetiracetam | 12 | $345 |
| Gabapentin | 23 | $247 |
| Levothyroxine Sodium | 24 | $241 |
| Cyclobenzaprine Hcl | 33 | $234 |
| Metoprolol Tartrate | 16 | $229 |
| Pantoprazole Sodium | 14 | $220 |
| Cefdinir | 15 | $214 |
| Celecoxib | 11 | $203 |
| Nifedipine ErNifedipine | 19 | $194 |
| Fluticasone Propionate | 13 | $162 |
| Potassium Chloride | 11 | $124 |
| Atorvastatin Calcium | 24 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,269 | $9,87814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 general practice providers in Louisiana.
Other general practice in Jonesboro
- William CaldwellMetairie$943K
- William MaloneLafayette$46K
- Muhammad AnjumShreveport$33K
- Melissa RatliffBarksdale Afb$22K
- Louis PassauerMandeville$20K
- Stan Cowley JrMetairie$15K
- Justin TarverMonroe$11K
- Darrell BourgMarrero$10K
- Terry BillingsMetairie$10K
- Emily LittleInnis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.